[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"knee-pain-arthritis\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:knee-pain-arthritis":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,4,0,[8,49,82,108],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":30,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":37,"lastUpdatePostDateStruct":38,"startDateStruct":41,"completionDateStruct":43,"leadSponsor":45,"locationsCount":48},"100633115","imageless-navigation-versus-image-based-navigation-in-robotic-assisted-total-knee-arthroplasty-for-knee-osteoarthritis-100633115",false,"NCT07522489","Imageless Navigation Versus Image-Based Navigation in Robotic-Assisted Total Knee Arthroplasty for Knee Osteoarthritis","Outcomes of Robotic-Assisted Total Knee Arthroplasty With Imageless Navigation Versus Image-Based Navigation: A Randomised, Single-Blinded, Non-Inferiority Trial","Inclusion Criteria:\n\n1. Symptomatic, radiologically confirmed advanced osteoarthritis of the knee.\n2. Patients referred for primary robotic-assisted total knee arthroplasty.\n3. Patients in whom a correctly performed radiograph with designated sensors has confirmed the possibility of performing robotic-assisted total knee arthroplasty with image-based navigation.\n4. Patients capable of giving informed consent to participate in the study and willing to attend all follow-up visits.\n\nExclusion Criteria:\n\n1. No informed consent for the surgery.\n2. No informed consent for taking part in the study.\n3. Pregnancy.\n4. Active infections.\n5. Diagnosed comorbidities: autoimmune arthritis, malignant tumors, serious neurological disorders affecting a reliable functional outcome measurement (e.g., severe stroke, severe Parkinson's disease).","ALL","18 Years",{"count":19,"type":20},146,"ESTIMATED","INTERVENTIONAL",[23],"NA","The goal of this clinical trial is to learn if imageless navigation is not inferior to image-based navigation in robotic-assisted total knee arthroplasty (RA-TKA) for treating patients with knee osteoarthritis.\n\nThe main questions the study aims to answer are:\n\n1. Does imageless procedure provide functional results comparable to those of image-based navigation?\n2. Are there differences in postoperative complications patients may experience after RA-TKA with imageless and image-based navigation? Researchers will compare imageless navigation with image-based navigation used in total knee arthroplasty to assess whether imageless navigation is comparable for the treatment of knee osteoarthritis.\n\nParticipants will:\n\n1. Answer survey questions about knee pain and function before RA-TKA.\n2. Undergo RA-TKA with imageless navigation or image-based navigation.\n3. Visit the Clinic after 6 months and 12 months after surgery for checkups and to answer the same survey questions about postoperative knee pain and function.",[26,27,28,29],"Osteoarthritis (OA) of the Knee","Knee Pain Arthritis","Total Knee Arthroplasty (TKA)","Robotic Assisted Arthroplasty",[31,32,33,34,35],"Knee Osteoarthritis","Robotic-Assisted Total Knee Arthroplasty","Patient Reported Outcome Measures","Imageless Navigation","Image-based Navigation","NOT_YET_RECRUITING","2026-04-07",{"date":39,"type":40},"2026-04-13","ACTUAL",{"date":42,"type":20},"2026-05",{"date":44,"type":20},"2029-01",{"name":46,"class":47},"Medical University of Warsaw","OTHER",1,{"id":50,"slug":51,"hasResults":11,"nctId":52,"briefTitle":53,"officialTitle":53,"acronym":4,"eligibilityCriteria":54,"healthyVolunteers":11,"sex":16,"minAge":55,"maxAge":56,"enrollmentInfo":57,"targetDuration":4,"studyType":21,"phases":59,"briefSummary":60,"conditions":61,"keywords":64,"overallStatus":72,"whyStopped":4,"lastUpdateSubmitDate":73,"lastUpdatePostDateStruct":74,"startDateStruct":76,"completionDateStruct":77,"leadSponsor":79,"locationsCount":81},"100623407","effects-of-diagonal-proprioceptive-neuromuscular-facilitation-patterns-on-pain-and-functional-outcomes-in-patients-with-knee-osteoarthritis-100623407","NCT07396233","Effects of Diagonal Proprioceptive Neuromuscular Facilitation Patterns on Pain and Functional Outcomes in Patients With Knee Osteoarthritis","Inclusion Criteria:\n\n* Both male and females with an age range between 40-60 years.\n* Patients diagnosed with unilateral or bilateral Knee OA.\n* Grade-II or grade-III on kellgren and Lawrence classification.\n* Patients having pain intensity more than 3.4 cm on VAS as minimum cut off value.\n* Duration of knee OA more than 3 months (chronic).\n\nExclusion Criteria:\n\n* Patients with any neurological disorder.\n* History of lower limb arthroplasty or any other knee surgery.\n* Septic knee arthritis.\n* Inflammatory rheumatic disease such as rheumatoid arthritis and gout.\n* Cancer or any other malignancy such as bone tumor.\n* Knee deformities such as contracture, genu valgum and genu varum.\n* History of ligamentous injury and meniscal tear.","40 Years","60 Years",{"count":58,"type":20},150,[23],"A randomized controlled trial will be conducted at the Department of Physiotherapy, Dr. Ziauddin Hospital and Al-Rayaz Hospital, Karachi, Pakistan. A total of 150 patients diagnosed with knee osteoarthritis, aged between 40-60 years, will be recruited through a non-probability purposive sampling technique. Written informed consent will be obtained from all eligible participants prior to enrollment. The participants will be randomly allocated by the help of computer generated randomization sheet, into two groups i.e. experimental and the control group, with 75 participants in each group. Group A (experimental group) will receive diagonal proprioceptive neuromuscular facilitation (PNF) pattern exercises, while Group B (control group) will receive conventional strength training exercises. Heat therapy will be administered to both groups. All participants will be assessed using a standardized assessment form. Outcome measures will include pain intensity, knee range of motion, functional disability, hamstring flexibility, dynamic balance, and fatigue level. A single blinded assessor will assess all participants at baseline and at post intervention. Treatment sessions will be given thrice a week on alternate days for 6 weeks.",[62,63,27],"Knee Osteoarthristis","Osteearthritis",[31,65,66,67,68,69,70,71],"Functional Disability","Knee Pain","Conventional Training","Osteoarthritis","Arthritis","Musculoskeletal Disease","Joint Disease","RECRUITING","2026-02-07",{"date":75,"type":40},"2026-02-11",{"date":73,"type":40},{"date":78,"type":20},"2027-02-22",{"name":80,"class":47},"University of Karachi",2,{"id":83,"slug":84,"hasResults":11,"nctId":85,"briefTitle":86,"officialTitle":87,"acronym":4,"eligibilityCriteria":88,"healthyVolunteers":11,"sex":16,"minAge":89,"maxAge":4,"enrollmentInfo":90,"targetDuration":4,"studyType":21,"phases":92,"briefSummary":93,"conditions":94,"keywords":4,"overallStatus":72,"whyStopped":4,"lastUpdateSubmitDate":97,"lastUpdatePostDateStruct":98,"startDateStruct":100,"completionDateStruct":102,"leadSponsor":104,"locationsCount":107},"100613530","long-term-study-of-cartipro-for-knee-pain-due-to-osteoarthritis-or-cartilage-damage-100613530","NCT07267793","Long-Term Study of CartiPRO for Knee Pain Due to Osteoarthritis or Cartilage Damage","Long-term Efficacy and Safety of CartiPRO Injection to Alleviate Knee Pain in Patients With Osteoarthritis and\u002For Diverse Cartilage Defects: a Multicenter, Single-blind, Randomized, Non-inferiority, Sponsor Initiated Trial","Inclusion Criteria\n\n* Age 19 years and older\n* Diagnosed with unilateral or bilateral knee osteoarthritis according to American College of Rheumatology (ACR) criteria, with at least 3 of the following 6 features:\n\n  * Age ≥50 years\n  * Morning stiffness \\\u003C30 minutes\n  * Crepitus on active motion\n  * Bony tenderness\n  * Bony enlargement\n  * No palpable warmth\n* Radiographic evidence of Kellgren-Lawrence grade I, II, or III osteoarthritis within 6 months prior to screening or at screening visit\n* Weight-bearing pain Visual Analogue Scale (VAS) score ≥40 mm in at least one knee joint at screening\n* Able to walk without assistive devices (walkers or canes), OR if using a walking aid routinely for past 6 months, able to continue using the same device throughout the study\n* Able to understand and complete efficacy assessment questionnaires\n* Willing and able to provide written informed consent\n\nExclusion Criteria\n\n* Body Mass Index (BMI) ≥32 kg\u002Fm²\n* Chronic inflammatory joint disease (e.g., rheumatoid arthritis)\n* Inflammatory joint disease (e.g., septic arthritis)\n* Secondary knee osteoarthritis due to ochronosis, hemochromatosis, or systemic disease\n* Painful musculoskeletal conditions (e.g., Sudeck's atrophy, Paget's disease, herniated intervertebral disc)\n* Polyarticular disease with severe osteoarthritis in other joints (e.g., hip) that may affect knee pain evaluation\n* Radiographic evidence of definite loss of patellofemoral joint space\n* Moderate to severe joint effusion confirmed by positive patellar tap test or equivalent\n* History of myocardial infarction, congestive heart failure, other serious cardiac disease, or uncontrolled hypertension (≥140\u002F90 mmHg despite treatment with ≥3 antihypertensive agents)\n* History of autoimmune disease\n* Active infection requiring parenteral antibiotics\n* History of psychiatric disorder or epilepsy\n* Cancer diagnosis within 5 years prior to screening\n* Uncontrolled type 1 or type 2 diabetes mellitus (HbA1c \\>7%)\n* Surgical procedures (including arthroscopy) on target knee within 1 year (surgery on contralateral knee or hip may be exclusionary if it could affect target knee assessment)\n* Intra-articular corticosteroid injection into target knee within 12 weeks\n* Systemic corticosteroid use within 4 weeks (topical and inhaled corticosteroids permitted)\n* Surgery or radiation therapy to knee joint within 12 weeks, or not fully recovered from side effects\n* Immunosuppressive therapy (e.g., Cyclosporine A, Azathioprine) within 6 weeks\n* Intra-articular injections (e.g., hyaluronic acid) into knee joint within 6 months\n* Prohibited concomitant medications within 2 weeks (unless washout period is adequate)\n* Anticoagulants (e.g., warfarin, NOACs), antiplatelet agents (e.g., aspirin \\>100 mg\u002Fday, clopidogrel; low-dose aspirin ≤100 mg\u002Fday permitted), thrombolytic agents (e.g., urokinase, alteplase), or Vitamin E \\>1000 IU\u002Fday within 2 weeks (unless adequate washout)\n* Habitual use (≥3 months) of psychoactive drugs or narcotic analgesics that may affect pain perception\n* History of cell therapy or gene therapy to target joint\n* Planned cell therapy or gene therapy to target joint\n* Abnormal laboratory values at screening:\n* ALT, AST, BUN, or serum creatinine \\>2× upper limit of normal\n* Engaged in high-intensity aerobic or heavy anaerobic exercise that may affect the knee joint\n* Dermatological disease at injection site or site deemed unsuitable for injection\n* Ligament instability of Grade II or higher in target knee (Grade 0: none; Grade I: 0-5 mm; Grade II: 5-10 mm; Grade III: \\>10 mm)\n* Known hypersensitivity to investigational product or its components\n* Pregnant or breastfeeding women\n* Women or men of childbearing potential unwilling to use acceptable contraception during study (acceptable methods: intrauterine device, tubal ligation, sterilization surgery, condom or diaphragm with spermicide, natural family planning)\n* Participation in another clinical trial within 4 weeks\n* Cognitive impairment or dementia preventing informed consent\n* Any other condition that makes the subject unsuitable for study participation per investigator judgment","19 Years",{"count":91,"type":20},194,[23],"This clinical trial aims to evaluate and compare the efficacy and safety of CartiPRO, an approved intra-articular atelocollagen injection, versus Synovian injection for the relief of knee pain in patients with knee osteoarthritis. The investigational device is administered intra-articularly, with a second injection given 24 weeks after the first dose. Primary and secondary endpoints include changes in pain scores (VAS), functional assessments (WOMAC, SF-36), and safety evaluations over a 36-week period.",[68,27,95,31,96],"Cartilage Defects of the Knee","Degenerative Joint Disease of Knee","2026-01-15",{"date":99,"type":40},"2026-01-20",{"date":101,"type":40},"2025-07-03",{"date":103,"type":20},"2026-10",{"name":105,"class":106},"DALIM TISSEN Co., Ltd.","INDUSTRY",5,{"id":109,"slug":110,"hasResults":11,"nctId":111,"briefTitle":112,"officialTitle":113,"acronym":4,"eligibilityCriteria":114,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":115,"targetDuration":4,"studyType":21,"phases":117,"briefSummary":118,"conditions":119,"keywords":121,"overallStatus":72,"whyStopped":4,"lastUpdateSubmitDate":126,"lastUpdatePostDateStruct":127,"startDateStruct":129,"completionDateStruct":131,"leadSponsor":133,"locationsCount":48},"100606699","neurolysis-for-the-treatment-of-medial-chronic-knee-pain-due-to-osteoarthritis-100606699","NCT07178951","Neurolysis for the Treatment of Medial Chronic Knee Pain Due to Osteoarthritis","Safety and Feasibility of the Neurolyser XR Device for the Treatment of Predominantly Medial Chronic Knee Pain Due to Osteoarthritis","Inclusion Criteria:\n\n1. Moderate to severe, predominantly medial chronic knee pain\n2. Age adult \\>18 years old\n3. WOMAC Score of 30 or higher\n4. NRS\\>6 with ambulation\n5. Radiological confirmation of knee osteoarthritis (Kellgren-Lawrence Scale: 2-4)\n6. Participants in whom the measured skin to bone depth is 2-6 cm using imaging ultrasound and ultrasound gel pad in the upper medial and lower medial joint capsule targets.\n\nExclusion Criteria:\n\n1. Individuals meeting any of the following criteria are not eligible for participation in this study:\n2. Individuals after any surgery associated with altered integrity of bone structure\n3. Individuals with severe pain in the second knee\n4. Individuals unable to understand and complete the research questionnaires in the official language\n5. Individuals presenting with any severe medical condition preventing the participant from safely and effectively being treated in the study or reporting study outcomes, per PI decision\n6. Individuals with extensive scarring of the skin and tissue overlying the treatment area\n7. Individuals enrolled in or planned to be enrolled in another clinical trial during the duration of this research project\n8. Individuals with active inflammatory (e.g., rheumatoid) arthritis\n9. Individuals with concomitant mental health disorders, excluding compensated mood disorders\n10. Individuals with altered perception and processing of pain: Average NRS \\> 9, PCS\\>30, SSS-8 \\> 11, CSI\\>40 \\[46\\], \\[47\\], \\[48\\]\n11. Individuals with a first-degree family member already enrolled in this study\n12. Individuals who are scheduled for any interventional\u002Fsurgical procedure within 3 months from the screening date, excluding trivial surgeries (e.g., cataract, skin tumors)\n13. Inability to attend follow-up visits and physiotherapy due to travel distance or other restrictions\n14. Symptomatic multifocal nociplastic chronic pain (e.g., fibromyalgia, generalized osteoarthritis) or any other chronic pain condition that could influence symptoms.\n15. Participants who have undergone radiofrequency ablation of the genicular nerves in the planned treatment limb within the preceding 6 months.",{"count":116,"type":20},10,[23],"This study involves the use of sound waves to block pain signals caused by osteoarthritis of the knee. The sound waves are tightly focused on a specific area of the nerve. The sound waves cause a break in the nerve which carries pain signals. Sound waves transmit through the skin so there is no need for needles. The procedure takes approximately one hour. The device has been approved in Health Canada and Europe for the treatment of lower back pain. This study is to evaluate the use of the same device for people in Canada who have knee pain related to osteoarthritis.",[26,27,120],"Chronic Knee Pain",[122,123,124,125],"osteoarthritis","knee pain","focused ultrasound","nerve ablation","2026-01-05",{"date":128,"type":40},"2026-01-07",{"date":130,"type":20},"2026-01",{"date":132,"type":20},"2026-12",{"name":134,"class":106},"FUSMobile Inc."]